Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyCellularComponent	anchoring collagen complex	COL7A1 COL14A1	1.29e-04	3	138	2	GO:0030934
GeneOntologyCellularComponent	postsynaptic specialization	SEMA4B ARHGAP32 MAP1A ZDHHC5 SYNPO GRIN2C PRR7 SLC6A9 SHANK2 INSYN2B SCRIB SAMD14	1.30e-04	503	138	12	GO:0099572
GeneOntologyCellularComponent	postsynaptic density	SEMA4B ARHGAP32 MAP1A SYNPO GRIN2C PRR7 SLC6A9 SHANK2 INSYN2B SCRIB SAMD14	2.06e-04	451	138	11	GO:0014069
GeneOntologyCellularComponent	asymmetric synapse	SEMA4B ARHGAP32 MAP1A SYNPO GRIN2C PRR7 SLC6A9 SHANK2 INSYN2B SCRIB SAMD14	3.32e-04	477	138	11	GO:0032279
HumanPheno	Phthisis bulbi	HMX1 BCOR COL18A1 BRD4	4.17e-06	17	35	4	HP:0000667
Domain	Ig-like_fold	SEMA4B COL7A1 LILRA3 EPM2A UNC5B NRG2 KIR2DS2 KIAA0319 SHANK2 FCGRT MICB COL14A1 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2 HCFC1	4.18e-06	706	137	18	IPR013783
Domain	SAM_1	PPFIA3 PHC3 SHANK2 SAMD14 GAREM1	1.42e-04	68	137	5	PF00536
Domain	AXH	HBP1 ATXN1	1.59e-04	3	137	2	SM00536
Domain	AXH	HBP1 ATXN1	1.59e-04	3	137	2	PF08517
Domain	Ataxin_AXH_dom	HBP1 ATXN1	1.59e-04	3	137	2	IPR003652
Domain	AXH	HBP1 ATXN1	1.59e-04	3	137	2	PS51148
Domain	SAM/pointed	ETV6 PPFIA3 PHC3 SHANK2 SAMD14 GAREM1	2.24e-04	117	137	6	IPR013761
Domain	LLGL	LLGL2 LLGL1	3.17e-04	4	137	2	PF08366
Domain	Lethal2_giant	LLGL2 LLGL1	3.17e-04	4	137	2	IPR000664
Domain	LLGL2	LLGL2 LLGL1	3.17e-04	4	137	2	IPR013577
Domain	-	COL7A1 LILRA3 EPM2A UNC5B NRG2 KIR2DS2 FCGRT MICB COL14A1 KIR2DL2 KIR2DL3 KIR2DS1 KIR3DL2 HCFC1	3.73e-04	663	137	14	2.60.40.10
Domain	ig	LILRA3 KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	5.10e-04	190	137	7	PF00047
Domain	Immunoglobulin	LILRA3 KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	5.10e-04	190	137	7	IPR013151
Domain	SAM_DOMAIN	PPFIA3 PHC3 SHANK2 SAMD14 GAREM1	6.74e-04	95	137	5	PS50105
Domain	SAM	PPFIA3 PHC3 SHANK2 SAMD14 GAREM1	7.41e-04	97	137	5	IPR001660
Domain	VWA	COL7A1 CACHD1 PARP4 COL14A1	7.57e-04	56	137	4	PF00092
Domain	IG_LIKE	LILRA3 UNC5B NRG2 KIR2DS2 FCGRT MICB KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.00e-03	491	137	11	PS50835
Pathway	KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY	PIK3R2 MICB KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.81e-05	137	95	7	M5669
Pubmed	Assessment of killer cell immunoglobulinlike receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	8.63e-13	10	142	6	12559621
Pubmed	Frequencies of killer immunoglobulin-like receptor genotypes influence susceptibility to spontaneous abortion.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.22e-11	14	142	6	19875891
Pubmed	Multiple sclerosis associates with LILRA3 deletion in Spanish patients.	LILRA3 KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	1.22e-11	14	142	6	19421224
Pubmed	Distribution of killer cell immunoglobulin-like receptor genes in the Chinese Han population.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.22e-11	14	142	6	15896204
Pubmed	Killer cell immunoglobulin-like receptor gene diversity in a Caucasian population of southern Brazil.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	2.02e-11	15	142	6	20082646
Pubmed	Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	2.02e-11	15	142	6	19926642
Pubmed	[Killer cell immunoglobin-like receptor and its ligand gene polymorphisms in Hunan Han patients with type 1 diabetes].	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	2.02e-11	15	142	6	20356536
Pubmed	Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	2.02e-11	15	142	6	20643584
Pubmed	KIR genes polymorphism in Argentinean Caucasoid and Amerindian populations.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	2.02e-11	15	142	6	17498266
Pubmed	Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	2.02e-11	15	142	6	19326408
Pubmed	Killer cell immunoglobulin-like receptor gene-cluster 3DS1-2DL5-2DS1-2DS5 predisposes susceptibility to Vogt-Koyanagi-Harada syndrome in Japanese individuals.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	19897003
Pubmed	Diversity of killer cell immunoglobulin-like receptor genes in Indonesian populations of Java, Kalimantan, Timor and Irian Jaya.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	19000141
Pubmed	Diversity of killer cell immunoglobulin-like receptor genes in Indonesian populations of Sumatra, Sulawesi and Moluccas Islands.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	20670355
Pubmed	Activating killer cell immunoglobulin-like receptor genes' association with recurrent miscarriage.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	19527230
Pubmed	Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	20652381
Pubmed	Asian population frequencies and haplotype distribution of killer cell immunoglobulin-like receptor (KIR) genes among Chinese, Malay, and Indian in Singapore.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	18668235
Pubmed	Influence of activating and inhibitory killer immunoglobulin-like receptors on predisposition to recurrent miscarriages.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	19279038
Pubmed	No association of KIR genes with Behcet's disease.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	17868255
Pubmed	A study of the killer cell immunoglobulin-like receptor gene KIR2DS1 in a Caucasoid Brazilian population with psoriasis vulgaris.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	18643961
Pubmed	Distribution of killer cell immunoglobulin-like receptor (KIR) genotypes in patients with familial Mediterranean fever.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	19309280
Pubmed	Report from the killer immunoglobulin-like receptor (KIR) anthropology component of the 15th International Histocompatibility Workshop: worldwide variation in the KIR loci and further evidence for the co-evolution of KIR and HLA.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	20331834
Pubmed	[Polymorphism of killer cell immunoglobulin-like receptors gene family in Zhejiang Han population].	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	16403292
Pubmed	HLA-DQA1*0505 sharing and killer immunoglobulin-like receptors in sub fertile couples: report from the 15th International Histocompatibility Workshop.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	3.22e-11	16	142	6	20210919
Pubmed	The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	4.97e-11	17	142	6	20173784
Pubmed	The role of killer immunoglobulin-like receptor haplotypes on the outcome of unrelated donor haematopoietic SCT for thalassaemia.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	4.97e-11	17	142	6	20173792
Pubmed	Role of killer cell immunoglobulin-like receptor gene content and human leukocyte antigen-C group in susceptibility to human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis in Peru.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	4.97e-11	17	142	6	20483367
Pubmed	[Effects of killer immunoglobulin-like receptor and human leukocyte antigen class I ligand on the prognosis of related donor hematopoietic stem cell transplantation].	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	4.97e-11	17	142	6	19968064
Pubmed	[Analysis of natural killer cell immunoglobulin-like receptor genes in Chinese].	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	4.97e-11	17	142	6	19218127
Pubmed	Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	4.97e-11	17	142	6	20878400
Pubmed	Killer cell immunoglobulin-like receptor gene diversity in the Tibetan ethnic minority group of China.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	4.97e-11	17	142	6	20650299
Pubmed	Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: possible association with susceptibility to the disease.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	4.97e-11	17	142	6	19450876
Pubmed	Distribution of killer-cell immunoglobulin-like receptor genes in Eastern mainland Chinese Han and Taiwanese Han populations.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	4.97e-11	17	142	6	19761533
Pubmed	NullHap--a versatile application to estimate haplotype frequencies from unphased genotypes in the presence of null alleles.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	5.86e-11	8	142	5	18681957
Pubmed	Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	7.43e-11	18	142	6	19630074
Pubmed	Influence of HLA class I and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression in a Manjako community in West Africa.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	7.43e-11	18	142	6	20519398
Pubmed	Signatures of natural selection and coevolution between killer cell immunoglobulin-like receptors (KIR) and HLA class I genes.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	7.43e-11	18	142	6	20200544
Pubmed	Combination of KIR 2DL2 and HLA-C1 (Asn 80) confers susceptibility to type 1 diabetes in Latvians.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	7.43e-11	18	142	6	19046302
Pubmed	Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	7.43e-11	18	142	6	19846535
Pubmed	Association of killer cell immunoglobulin-like receptors and human leukocyte antigen-C genotypes in South Brazilian with type 1 diabetes.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	7.43e-11	18	142	6	20580654
Pubmed	KIR and HLA gene combinations in Vogt-Koyanagi-Harada disease.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.08e-10	19	142	6	18571006
Pubmed	Association between killer-cell immunoglobulin-like receptor genotypes and leprosy in Brazil.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.08e-10	19	142	6	18778326
Pubmed	Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.08e-10	19	142	6	20600442
Pubmed	Killer cell immunoglobulin-like receptor gene diversity in a Southern Brazilian population from the state of Paraná.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.08e-10	19	142	6	18848853
Pubmed	Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS5 KIR3DL2	1.31e-10	9	142	5	7749980
Pubmed	Alternatively spliced forms of human killer inhibitory receptors.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS5 KIR3DL2	1.31e-10	9	142	5	8662091
Pubmed	Compound KIR-HLA genotype analyses in the Iranian population by a novel PCR-SSP assay.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.54e-10	20	142	6	20193031
Pubmed	Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	2.15e-10	21	142	6	19861144
Pubmed	Distribution of KIR genes in the population of unrelated individuals homozygous for ancestral haplotype AH8.1 (HLA-A1B8DR3).	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	2.94e-10	22	142	6	20492596
Pubmed	[Genotype analysis of killer cell immunoglobulin-like receptors in Graves' disease patients].	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	4.79e-10	11	142	5	19664392
Pubmed	Association of killer cell immunoglobulin-like receptor 2DL5 with systemic lupus erythematosus and accompanying infections.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	8.18e-10	12	142	5	20371502
Pubmed	Association of killer cell immunoglobulin-like receptors with primary Sjogren's syndrome.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	8.18e-10	12	142	5	19181658
Pubmed	[Relationship between CMV reactivation and KIR haplotype/HLA-Cw genotype in patients after unrelated-donor hematopoietic stem cell transplantation.].	KIR2DS2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	8.18e-10	12	142	5	20137308
Pubmed	Distribution of killer cell immunoglobulin-like receptors (KIR) and their HLA-C ligands in two Iranian populations.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	8.18e-10	12	142	5	19936734
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	SEMA4B RHBDF2 SIPA1L3 ZDHHC5 FBRSL1 FRYL CNTROB BAHD1 KIAA2013 NHSL1 PHLDB1 ARHGEF40 LLGL2 SHANK2 BRD4 DISP2 POLL SPEN HCFC1 WNK2 PRRC2B GAREM1	8.66e-10	1105	142	22	35748872
Pubmed	[Study on the polymorphism of killer cell immunoglobulin like receptor (KIR) gene with systemic lupus erythematosus of North population in China].	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	1.33e-09	13	142	5	18687225
Pubmed	KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	1.33e-09	13	142	5	19934297
Pubmed	Different KIRs confer susceptibility and protection to adults with latent autoimmune diabetes in Latvian and Asian Indian populations.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	1.33e-09	13	142	5	19120281
Pubmed	Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1	1.33e-09	5	142	4	16112031
Pubmed	Association of killer cell immunoglobulin-like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1	1.33e-09	5	142	4	18755860
Pubmed	Immunogenetic characteristics of patients with autoimmune gastritis.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.83e-09	29	142	6	20082482
Pubmed	[Genotype and haplotype analysis of killer cell immunoglobulin-like receptors in ankylosing spondylitis].	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR3DL2	2.05e-09	14	142	5	19489269
Pubmed	Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.	KIR2DS2 KIR2DL2 KIR2DS1 KIR2DS5 KIR3DL2	2.05e-09	14	142	5	18945962
Pubmed	Killer cell immunoglobulin-like receptors in HLA-B27-associated acute anterior uveitis, with and without axial spondyloarthropathy.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	3.07e-09	15	142	5	19850842
Pubmed	Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	3.07e-09	15	142	5	20207982
Pubmed	Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	3.07e-09	15	142	5	19493232
Pubmed	Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1	3.97e-09	6	142	4	17882223
Pubmed	Role of human leukocyte antigen, killer-cell immunoglobulin-like receptors, and cytokine gene polymorphisms in leptospirosis.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	6.13e-09	35	142	6	19683555
Pubmed	Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation.	KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	6.29e-09	17	142	5	19032228
Pubmed	KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	6.29e-09	17	142	5	19169284
Pubmed	Distribution of killer cell immunoglobulin-like receptor genes in the mestizo population from Venezuela.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS5 KIR3DL2	8.68e-09	18	142	5	20210918
Pubmed	Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes.	KIR2DS2 KIR2DL2 KIR2DS5 KIR3DL2	9.23e-09	7	142	4	14607943
Pubmed	Identification of seventeen novel KIR variants: fourteen of them from two non-Caucasian donors.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1	9.23e-09	7	142	4	11169255
Pubmed	The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.	ATN1 TROAP RBM4 FBRSL1 BCOR MIDEAS ALMS1 CCDC120 PRRC2B	1.40e-08	152	142	9	38360978
Pubmed	HLA and KIR frequencies in Sicilian Centenarians.	KIR2DS2 KIR2DL2 KIR2DS1 KIR2DS5 KIR3DL2	1.56e-08	20	142	5	20426625
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	MAPK8IP1 ARHGAP32 CENPE SIPA1L3 WDR18 SYNPO PPFIA3 BCOR ABLIM3 LUZP1 KIAA0319 SEPTIN3 SHANK2 RAB3IP DCHS1 SCRIB FRMPD3 WNK2 PRRC2B	1.57e-08	963	142	19	28671696
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	MIER2 SEMA4B ARHGAP32 SIPA1L3 ZDHHC5 ABLIM3 KIAA2013 SLC45A4 CEP350 PARP4 ALMS1 ADAMTS9 CEP72 SPON1	1.69e-08	493	142	14	15368895
Pubmed	Killer Immunoglobulin-Like Receptor 2DS2 (KIR2DS2), KIR2DL2-HLA-C1, and KIR2DL3 as Genetic Markers for Stratifying the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients.	KIR2DS2 KIR2DL2 KIR2DL3	6.66e-08	3	142	3	30696053
Pubmed	Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.	KIR2DS2 KIR2DL2 KIR2DS1	6.66e-08	3	142	3	19877200
Pubmed	Associations of killer cell immunoglobulin- like receptor genes with rheumatoid arthritis.	KIR2DS2 KIR2DL2 KIR2DL3	6.66e-08	3	142	3	22960345
Pubmed	Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.	KIR2DS2 KIR2DL2 KIR2DS1	6.66e-08	3	142	3	23380384
Pubmed	Imputation of KIR Types from SNP Variation Data.	KIR2DS2 KIR2DL2 KIR2DL3	6.66e-08	3	142	3	26430804
Pubmed	Cutting edge: selective expression of inhibitory or activating killer cell Ig-like receptors in circulating CD4+ T lymphocytes.	KIR2DS2 KIR2DL2 KIR2DL3	6.66e-08	3	142	3	18292496
Pubmed	Natural killer cells and immune surveillance.	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS5	8.60e-08	11	142	4	18830515
Pubmed	[Polymorphism of killer cell immunoglobulin-like receptor gene and its correlation with leukemia].	KIR2DS2 KIR2DL3 KIR2DS5 KIR3DL2	1.29e-07	12	142	4	17490516
Pubmed	A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.	ARHGAP32 UNC5B ZDHHC5 CACHD1 NHSL1 PHLDB1 LLGL2 LLGL1 PIK3R2 WDR20 SCRIB USP6NL	1.79e-07	421	142	12	36976175
Pubmed	Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility.	KIR2DS2 KIR2DL2 KIR2DL3	2.66e-07	4	142	3	16929347
Pubmed	KIR/HLA ligand incompatibility in kidney transplantation.	KIR2DS2 KIR2DL2 KIR2DL3	2.66e-07	4	142	3	18091530
Pubmed	Investigation of activating and inhibitory killer cell immunoglobulin-like receptors and their putative ligands in type 1 diabetes (T1D).	KIR2DL2 KIR2DL3 KIR2DS1	2.66e-07	4	142	3	26542066
Pubmed	The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis.	ARHGAP32 SIPA1L3 PPFIA3 PPP1R13L LUZP1 LRRC47 NHSL1 PHLDB1 PRRC2B	3.07e-07	218	142	9	33378226
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	CYC1 MAPK8IP1 ARHGAP32 MAP1A SIPA1L3 SYNPO PPFIA3 ABLIM3 LUZP1 LRRC47 NHSL1 PHLDB1 MGAT3 SHANK2 MICAL2 AJM1 SPON1 SCRIB PRKAG2 WNK2 PRRC2B	3.86e-07	1431	142	21	37142655
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	ARHGAP32 ATG13 PARP8 SIPA1L3 FRYL LUZP1 CEP350 NHSL1 PHLDB1 ALMS1 FAM13A ATXN1 BRD4 SCRIB REEP4 USP6NL	5.16e-07	861	142	16	36931259
Pubmed	E-cadherin interactome complexity and robustness resolved by quantitative proteomics.	ARHGAP32 SIPA1L3 ZDHHC5 PPP1R13L ABLIM3 LUZP1 NHSL1 LLGL1 SHANK2 CCDC120 SCRIB HCFC1 USP6NL	6.17e-07	565	142	13	25468996
Pubmed	In contrast to other stimulatory natural killer cell immunoglobulin-like receptor loci, several KIR2DS5 alleles predominate in African Americans.	KIR2DS2 KIR2DS1 KIR2DS5	6.62e-07	5	142	3	19410616
Pubmed	KIR gene in ethnic and Mestizo populations from Mexico.	KIR2DL2 KIR2DS1 KIR2DS5	6.62e-07	5	142	3	16698429
Pubmed	Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells.	KIR2DS2 KIR2DL3 KIR3DL2	6.62e-07	5	142	3	7716543
Pubmed	Analysis of candidate genes on chromosome 19 in coeliac disease: an association study of the KIR and LILR gene clusters.	LILRA3 KIR2DL2 KIR2DL3	6.62e-07	5	142	3	12121272
Pubmed	Diversity of the repertoire of p58 killer cell inhibitory receptors in a single individual.	KIR2DS2 KIR2DL3 KIR2DS1	6.62e-07	5	142	3	10424431
Pubmed	An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase.	ARHGAP32 RBM4 ZDHHC5 BCOR SLC6A9 LLGL1 CCDC120 USP6NL	8.19e-07	180	142	8	35198878
Pubmed	Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.	MAP1A SIPA1L3 BCOR CNTROB CEP350 ALMS1 ATXN1 SPEN	9.66e-07	184	142	8	32908313
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	ATN1 TEAD3 BCOR MIDEAS ASH2L ATXN1 BRD4 HCFC1 PRRC2B	1.71e-06	268	142	9	33640491
Interaction	EYA4 interactions	ATN1 TROAP RBM4 FBRSL1 BCOR MIDEAS LUZP1 ALMS1 CCDC120 PRRC2B	8.38e-06	243	141	10	int:EYA4
Interaction	B4GALT2 interactions	ARHGAP32 RNF31 RGL3 ETV6 BCOR PPP1R13L DCHS1	2.06e-05	119	141	7	int:B4GALT2
Interaction	CEP135 interactions	TBC1D19 ARHGAP32 SIPA1L3 CNTLN CNTROB LUZP1 CEP350 ALMS1 CEP72 PRRC2B	2.22e-05	272	141	10	int:CEP135
Interaction	KRT19 interactions	ARHGAP32 RNF31 BCOR CNTROB LUZP1 CEP350 ALMS1 ATXN1 CEP72 POLL	3.03e-05	282	141	10	int:KRT19
Cytoband	19q13.4	LILRA3 KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	5.62e-09	79	142	7	19q13.4
GeneFamily	CD molecules\|Killer cell immunoglobulin like receptors	KIR2DS2 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	2.27e-10	18	90	6	620
GeneFamily	Membrane associated guanylate kinases\|PDZ domain containing\|Scribble complex	LLGL2 LLGL1 SCRIB	4.75e-07	4	90	3	1224
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	LILRA3 KIR2DS2 CD5 KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	7.74e-04	394	90	8	471
GeneFamily	PDZ domain containing	SIPA1L3 SHANK2 SCRIB FRMPD3 PDZD2	9.73e-04	152	90	5	1220
GeneFamily	Sterile alpha motif domain containing	PPFIA3 PHC3 SHANK2 SAMD14	9.73e-04	88	90	4	760
GeneFamily	Collagens	COL7A1 COL18A1 COL14A1	1.55e-03	46	90	3	490
GeneFamily	Zinc fingers\|Zinc fingers PARP-type\|Poly(ADP-ribose) polymerases	PARP8 PARP4	3.17e-03	17	90	2	684
Coexpression	KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_AGE_UNKNOWN_CORRELATED_WITH_PROTECTION_56DY_NEGATIVE	KIR2DS2 SH2D2A KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5	2.62e-07	49	142	6	M40909
Coexpression	GSE5542_UNTREATED_VS_IFNA_TREATED_EPITHELIAL_CELLS_6H_UP	ERICH3 ATN1 RHBDF2 ETV6 SH2D2A LUZP1 LLGL2 ATXN1	1.40e-05	200	142	8	M6514
Coexpression	MENON_FETAL_KIDNEY_8_CONNECTING_TUBULE_CELLS	CYC1 RGL3 ZC3H13 COL18A1 PHLDB1 LLGL2 ARSD ADAMTS9 RAB3IP	1.59e-05	267	142	9	M39258
Coexpression	LEE_BMP2_TARGETS_UP	GALNT15 COL7A1 PDK4 RGL3 DGKA HBP1 GLMP SLC6A9 COL18A1 PHLDB1 FCGRT SPON1 DCHS1 SAMD14 GAA	2.29e-05	780	142	15	M2324
Coexpression	LEE_BMP2_TARGETS_UP	GALNT15 COL7A1 PDK4 RGL3 DGKA HBP1 GLMP SLC6A9 COL18A1 PHLDB1 FCGRT SPON1 DCHS1 SAMD14 GAA	3.29e-05	805	142	15	MM1067
Coexpression	LINDGREN_BLADDER_CANCER_CLUSTER_3_DN	SEMA4B COL7A1 RNF31 UNC5B DGKA ARHGEF40 ARSD ATXN1	3.36e-05	226	142	8	M11238
ToppCell	Parenchymal-NucSeq-Epithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ARHGAP32 SIPA1L3 CACHD1 NHSL1 LLGL2 SHANK2 MICAL2 GAREM1 PDZD2	1.35e-08	199	139	9	5cea0d9e261903e0eaad60c28a07dff72ce65027
ToppCell	Bronchial-NucSeq-Epithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ARHGAP32 CACHD1 NHSL1 LLGL2 SHANK2 MICAL2 GAREM1 PDZD2	2.18e-07	199	139	8	5f7da3eab58ace6cddb3179a415cd839d5767958
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Myeloid-Dendritic-conventional_dendritic_cell-DC_c1-CLEC9A\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	TBC1D19 SEMA4B RNF31 TROAP SIPA1L3 BCOR PIK3R2	9.29e-07	166	139	7	c8fd241088de27c6e741a5dfee3cd770183b6bcb
ToppCell	PCW_07-8.5-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^high_distal_(10)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	LARGE2 RGL3 RFX6 COL18A1 LLGL2 UBXN2B SHANK2	2.29e-06	190	139	7	625c08a0e5227efc46daa512fd579c3938ff76c7
ToppCell	PCW_07-8.5-Epithelial-Epithelial_neuroendo\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	LARGE2 ERICH3 KCNH7 RGL3 RFX6 LLGL2 SHANK2	2.62e-06	194	139	7	b30379f8dc41c86c746af9930541fbb4819d8fa0
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-immature_mesenchymal_cell-Mesoderm_1_(HAND1+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ESPNL CDH24 CCDC120 INSYN2B VSIG10L2 HCFC1	6.63e-06	146	139	6	40784fd7ef856f64edfb5a054c0c5d95c8150b20
ToppCell	10x5'-Lung-Lymphocytic_T_CD4/8-lo\|Lung / Manually curated celltypes from each tissue	TROAP PARP8 SH2D2A SHANK2 KIR2DL3 KIR3DL2	1.16e-05	161	139	6	a1f10e04836848b1deaf295fae033f54d1572fcd
ToppCell	Transplant_Alveoli_and_parenchyma-Epithelial-Basal_1\|Transplant_Alveoli_and_parenchyma / Tissue, Lineage and Cell class of Lung Cells from 10X	COL7A1 ERICH3 CENPE TEAD3 LRRC47 SHANK2	1.58e-05	170	139	6	aabe993c9f337b1caaeb0e64626a3920579c41b7
ToppCell	AT1-AT2_cells-Donor_06\|World / lung cells shred on cell class, cell subclass, sample id	SYNPO TEAD3 PHLDB1 LLGL2 ADAMTS9 PDZD2	1.86e-05	175	139	6	bdd85ba280648a0283c1984662a34c7b840f64dd
ToppCell	368C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-\|368C / Donor, Lineage, Cell class and subclass (all cells)	LARGE2 TROAP ZGRF1 CACHD1 KIAA0319 CEP72	1.86e-05	175	139	6	fd8b5b756f3df4a04938785f3d9edbb6f1cd20f6
ToppCell	368C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)\|368C / Donor, Lineage, Cell class and subclass (all cells)	LARGE2 TROAP ZGRF1 CACHD1 KIAA0319 CEP72	1.86e-05	175	139	6	36c140540497bbe1c5f08fac2d94f08cac18fabb
ToppCell	droplet-Lung-30m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l2-17-52\|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	COL7A1 CENPE TROAP RBM4 SHD REEP4	2.11e-05	179	139	6	af03705a783e77f75c44fdfa793cfdccbf9dd91c
ToppCell	3'-GW_trimst-2-LargeIntestine-Epithelial-epithelial_progenitor_cell-TA\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	COL7A1 CENPE TROAP SH2D2A NHSL1 FRMPD3	2.18e-05	180	139	6	271ee52ed8f21f78ddf68e52fc88fe582701675e
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	TBC1D19 MAP1A DGKA CD5 FAM13A ATXN1	2.18e-05	180	139	6	d9dae9db8e17f6990032ee6cfa8393fae4768ca5
ToppCell	3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells-NK_cells_L.1.3.2.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CENPE TROAP ESPNL SH2D2A ALMS1 KIR2DL3	2.25e-05	181	139	6	e4dbc09f0210de465d8347969b301c22463a2b7d
ToppCell	facs-Lung-Endomucin-24m-Mesenchymal-pericyte_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP1A SIPA1L3 SHD USP6NL GAREM1 PDZD2	2.32e-05	182	139	6	be9c312a44868d4ee266a64d066feb8c5bce5687
ToppCell	facs-Lung-Endomucin-24m-Mesenchymal-Pericyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP1A SIPA1L3 SHD USP6NL GAREM1 PDZD2	2.32e-05	182	139	6	74dbb706bcaa0f8c922bf3b0424bce5bb27167fa
ToppCell	3'-Child04-06-SmallIntestine-Mesenchymal-fibroblastic-Stromal_4_(MMP1+)\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MAPK8IP1 CDO1 UNC5B RGL3 NRG2 COL14A1	2.39e-05	183	139	6	269afec240a756eec3bbae5f30ec784281af3433
ToppCell	droplet-Spleen-SPLEEN-1m-Lymphocytic-immature_NKT_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CENPE TROAP CNTLN TEAD3 CD5 CCDC106	2.54e-05	185	139	6	736bf89a7a1a840ab6920060f2d98598332065a0
ToppCell	10x5'v1-week_12-13-Endothelial-stroma-sinusoidal_EC\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	GALNT15 SYNPO ABLIM3 ADAMTS9 DCHS1 INSYN2B	2.62e-05	186	139	6	e8ead5634686ebaa6a230eea69795d923ce9939d
ToppCell	droplet-Lung-21m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l27\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SYNPO PPP1R13L SLC45A4 COL18A1 MICAL2 DCHS1	2.62e-05	186	139	6	c116cc9f41971622264434ebe29d18e719b0ae19
ToppCell	TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1\|TCGA-Pancreas / Sample_Type by Project: Shred V9	ZC3H13 LUZP1 CEP350 PHC3 PARP4 ALMS1	2.62e-05	186	139	6	03db813598b67b1e08f759758a1c2023396921fa
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	RGL3 SIPA1L3 PPP1R13L LLGL2 SHANK2 ARSD	2.70e-05	187	139	6	58d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCell	PBMC-Control-Lymphocyte-B-B_cell-B_memory\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	LARGE2 SEMA4B RHBDF2 SYNPO MGAT3 USP6NL	2.78e-05	188	139	6	9256c5f45c97df209bb9c322c3b557d4f726a333
ToppCell	PCW_07-8.5-Epithelial-Epithelial_alveolar-distal-epi_SFTPC^high_distal_(9)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	LARGE2 RFX6 LLGL2 UBXN2B SHANK2 WNK2	2.87e-05	189	139	6	5d9da836ce4308b8458bb3be3871a0aca734b6cd
ToppCell	PBMC-Control-Lymphocyte-B-B_cell-B_memory-B_memory-3\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	LARGE2 SEMA4B RHBDF2 SYNPO MGAT3 USP6NL	2.87e-05	189	139	6	ac0203f17b481d608587113ea2de0f383b29ed27
ToppCell	PBMC-Control-Lymphocyte-B-B_cell-B_memory\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	LARGE2 SEMA4B RHBDF2 SYNPO MGAT3 USP6NL	3.04e-05	191	139	6	03f6da73e7b706252d2096507222229c4101a27b
ToppCell	PBMC-Control-Lymphocyte-B-B_cell-B_memory-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	LARGE2 SEMA4B RHBDF2 SYNPO MGAT3 USP6NL	3.04e-05	191	139	6	578b58782e816ecaeabfbc616ceb1dcd53ee428b
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RGL3 CACHD1 NHSL1 LLGL2 SHANK2 PDZD2	3.04e-05	191	139	6	ca5669bd6f4a17471acae3eb229f845cc2e08efa
ToppCell	Epithelial\|World / Lineage, Cell type, age group and donor	CACHD1 LLGL2 SHANK2 MICAL2 GAREM1 PDZD2	3.13e-05	192	139	6	499e8893afea5e6d3371e0bd018f7e86a524d669
ToppCell	Adult-Epithelial\|Adult / Lineage, Cell type, age group and donor	CACHD1 LLGL2 SHANK2 MICAL2 GAREM1 PDZD2	3.13e-05	192	139	6	efb962a5fd3b9bdfd8cf8d13c435e29c8271713e
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RGL3 CACHD1 NHSL1 SHANK2 MICAL2 PDZD2	3.13e-05	192	139	6	fb2f0e897228f808d9ff734ad05e9b49dc38fa50
ToppCell	B_cells-Activate_B_cells\|World / Immune cells in Kidney/Urine in Lupus Nephritis	LARGE2 SEMA4B RHBDF2 SYNPO MGAT3 USP6NL	3.22e-05	193	139	6	b6da81920cf2e55f87ec8d4b2b5530cbf7ba2155
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	RGL3 SIM2 LLGL2 SHANK2 RAB3IP GAREM1	3.32e-05	194	139	6	93c68c31e39fa44c1d05d7d4997f4f086da4e738
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	RGL3 SIPA1L3 SIM2 LLGL2 SHANK2 GAREM1	3.42e-05	195	139	6	6477e6e7be5bd8eb99119a12ae16334ccddecd43
ToppCell	PCW_10-12\|World / Celltypes from embryonic and fetal-stage human lung	CDO1 PDK4 HBP1 ABLIM3 FCGRT SPON1	3.62e-05	197	139	6	47fd8b0d596c5db1a722473c8efbb17a6bbe7538
ToppCell	10x5'v1-week_12-13-Endothelial-stroma\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	SYNPO ABLIM3 NHSL1 ADAMTS9 DCHS1 INSYN2B	3.72e-05	198	139	6	122215d9288533ad03562cf777e846504863df9a
ToppCell	10x5'v1-week_12-13-Endothelial\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	SYNPO ABLIM3 NHSL1 ADAMTS9 DCHS1 INSYN2B	3.72e-05	198	139	6	307dd09e6bc820a148f3000f18dae7aedba4be0b
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	ARHGAP32 SIPA1L3 NHSL1 SHANK2 ATXN1 PDZD2	3.72e-05	198	139	6	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	Bronchial-NucSeq-Epithelial-Epi_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CACHD1 NHSL1 LLGL2 SHANK2 MICAL2 PDZD2	3.83e-05	199	139	6	725610310e5c5fd7120c0be9acb55bf152026ddd
ToppCell	COVID_non-vent-Lymphocytic-ILC\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	ERICH3 PARP8 SH2D2A LLGL2 KIR2DL2 KIR2DL3	3.83e-05	199	139	6	df4f7d5be099e3e6054f3b812ccf70251664e4c0
ToppCell	COVID_non-vent-Lymphocytic-ILC-NK_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	ERICH3 PARP8 SH2D2A LLGL2 KIR2DL2 KIR2DL3	3.83e-05	199	139	6	ed35d747f11f6ea6a5cb7061057f0a98d9e0db99
ToppCell	Adult-Mesenchymal-chondrocyte-D122\|Adult / Lineage, Cell type, age group and donor	SIM2 ABLIM3 LLGL1 ZBTB3 B4GALT3	1.02e-04	148	139	5	81a1e6fdd942a612bf523c59b8b4974f6ca1fdce
ToppCell	LPS-IL1RA+antiTNF-Unknown-Endothelial-Myofibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TBC1D19 ASH2L DCHS1 CCDC120 REEP4	1.22e-04	154	139	5	16fdafb5c64d2db321554f87129a962d113f1668
ToppCell	10x5'-Lung-Lymphocytic_T_CD4/8-lo-Tgd_CRTAM\|Lung / Manually curated celltypes from each tissue	PARP8 SH2D2A SHANK2 KIR2DL3 KIR3DL2	1.30e-04	156	139	5	0ea6ca3f38109151a2a4fdf63a4f009929cdcc40
ToppCell	368C-Lymphocytic-NK_cells\|368C / Donor, Lineage, Cell class and subclass (all cells)	CENPE ZGRF1 SH2D2A KIR2DL3 KIR3DL2	1.34e-04	157	139	5	ef5c0ace4cd500b6cc50fb7076298f3d3543b40c
ToppCell	Smart-seq2-tissue-resident_(Smart-seq2)-hematologic-erythrocytic-erythrocyte\|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	TROAP SLC6A9 MGAT3 CBY2 INSYN2B	1.55e-04	162	139	5	25a11e4c6304324310b33a33331ebc812d045d4a
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c12-MKI67-TYROBP\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	CENPE TROAP CDH24 KIR2DL3 KIR3DL2	1.60e-04	163	139	5	466c8129852a5b16cd9fcc6b79e799abc21bb21a
ToppCell	E16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal-Mature_Fibroblast_1\|E16.5-samps / Age Group, Lineage, Cell class and subclass	PDK4 GRIN2C GPR88 SPON1 COL14A1	1.60e-04	163	139	5	f1ec2625b52664308968b01d8e0275e1e0751480
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Degenerative_Descending_Thin_Limb_Cell_Type_3\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SIM2 PARP4 SHANK2 ADAMTS9 PDZD2	1.64e-04	164	139	5	1cb5fbd7050650047ad6f2ca792118e98d58d22b
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c06-TNF\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	RGL3 SH2D2A LLGL2 SCRIB KIR2DL3	1.74e-04	166	139	5	217e0549f88819d02156ea64e8547b658b1c7aef
ToppCell	droplet-Heart-nan-18m-Mesenchymal-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARHGAP32 RGL3 XRCC3 MIDEAS GAA	1.74e-04	166	139	5	9adceb746e67e955fd8b3e0984f4eed44b64a270
ToppCell	390C-Lymphocytic-ILC-ILC-2\|390C / Donor, Lineage, Cell class and subclass (all cells)	MIER2 ZGRF1 HBP1 CD5 EPS8L3	1.84e-04	168	139	5	2781dd6b369427a94c5059b44b4c8f023f5f2988
ToppCell	TCGA-Bladder-Primary_Tumor-Urothelial_Carcinoma-Non-Papillary_Muscle_Invasive_Urothelial_Carcinoma-5\|TCGA-Bladder / Sample_Type by Project: Shred V9	MAPK8IP1 ERICH3 GRIN2C SHD SEPTIN3	1.89e-04	169	139	5	9c4e83fe8225d16173a103bf5a57b17d623be923
ToppCell	5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting-Basal_resting_L.0.0.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	LARGE2 COL7A1 NRG2 RFX6 PPP1R13L	1.94e-04	170	139	5	0cc20322cb3e3e7bbd4daad8785c99f80e355c16
ToppCell	5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	LARGE2 COL7A1 NRG2 RFX6 PPP1R13L	1.94e-04	170	139	5	2d880223d01bde4bf777bd6f50b7d2768489075f
ToppCell	facs-Heart-RV-18m-Mesenchymal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DET1 CNTROB PHLDB1 ALMS1 PIK3R2	1.94e-04	170	139	5	d7c9a604311974ff87ece43a0f8725a234d262f7
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CENPE TROAP ZGRF1 MICAL2 DISP2	1.99e-04	171	139	5	b0373ed8283ee1792b6a490bff93906546978593
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CENPE TROAP ZGRF1 MICAL2 DISP2	1.99e-04	171	139	5	b92963f9f247d2e5e2e6c51c6dbf70e527cd2f55
ToppCell	LV-13._Vascular_Smooth_Muscle\|LV / Chamber and Cluster_Paper	RGL3 ETV6 COL18A1 ADAMTS9 COL14A1	1.99e-04	171	139	5	e99ecae66530d1ae09330cee408c8f3950b87e67
ToppCell	Primary_Motor_Cortex_(M1)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1_FGFR3_MT1G\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PDK4 RGL3 GRIN2C NHSL1 SPON1	2.05e-04	172	139	5	55fba5ce0ead1114e1a76f67ad68432c6bac90e5
ToppCell	ASK440-Epithelial-Transformed_epithelium\|ASK440 / Donor, Lineage and Cell class of Lung cells from Dropseq	LARGE2 COL7A1 CNTROB ADAMTS9 DCHS1	2.05e-04	172	139	5	df3800bcd9777d02900eba0cfc26ab73de8a1d95
ToppCell	390C-Lymphocytic-ILC-ILC-2\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	MIER2 ZGRF1 COL18A1 ARHGEF40 EPS8L3	2.05e-04	172	139	5	84d16cd7f618c94888920680bdc9e7130d73fd75
ToppCell	15-Trachea-Immune-Hematopoietic,_Natural_Killer_Cell\|Trachea / Age, Tissue, Lineage and Cell class	SH2D2A MICB KIR2DL2 KIR2DL3 KIR3DL2	2.10e-04	173	139	5	6884af1492e8a3bb92a33303d4d5ec3343e88b00
ToppCell	facs-Marrow-KLS-3m-Lymphocytic-immature_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATG13 COL18A1 SPON1 WNK2 PRRC2B	2.10e-04	173	139	5	8bffd512a4e561e23cc04478e2ca6fd5d3771fe4
ToppCell	facs-Marrow-KLS-3m-Lymphocytic-immature_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATG13 COL18A1 SPON1 WNK2 PRRC2B	2.10e-04	173	139	5	3e3c61468e703330788a10d850ef41a85680f86d
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c08-IL2RB\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	RGL3 LLGL2 ADAMTS9 KIR2DL3 ZBTB3	2.10e-04	173	139	5	5295ed31648abf8edff214cf67cd4769f20f9e6d
ToppCell	Control-Lymphocyte-T_NK-gdT\|Control / Disease, Lineage and Cell Type	SH2D2A CDH24 LLGL2 FRMPD3 ERVFRD-1	2.16e-04	174	139	5	202d222a53f967cce172e5f3f1b40920ea13ec6c
ToppCell	facs-Heart-RV-18m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DET1 CNTROB PHLDB1 ALMS1 PIK3R2	2.28e-04	176	139	5	c0a084f7a8645262d61971f094689e02bf15b113
ToppCell	facs-Heart-RV-18m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DET1 CNTROB PHLDB1 ALMS1 PIK3R2	2.28e-04	176	139	5	cccf9201f6e2da7524b911a5961d3b227edab222
ToppCell	LPS-IL1RA+antiTNF\|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CNTLN SHANK2 FAM13A SPON1 COL14A1	2.34e-04	177	139	5	b7fee75de7e96924af488a5baa2334711889ae7c
ToppCell	368C-Myeloid-Macrophage-SPP1+_Macrophage_3\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	COL7A1 RGL3 SYNPO ALMS1 GAREM1	2.40e-04	178	139	5	9d575902d3dbe33437c9d4200df093a741269803
ToppCell	E16.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_G2M\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CDO1 CENPE TROAP LRRC47 POLL	2.40e-04	178	139	5	c87945146b2734141f07b39d268e0d8086ee0364
ToppCell	tumor_Lymph_Node_/_Brain-Myeloid_cells-Activated_DCs\|Myeloid_cells / Location, Cell class and cell subclass	SIM2 BCOR NHSL1 COL14A1 DISP2	2.46e-04	179	139	5	5f7e6670a0e906a0a5bc75735408361d88e78fa2
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	TROAP ZGRF1 XRCC3 KIAA0319 CEP72	2.46e-04	179	139	5	88d44b04eb5c079531db663ed98ddb20b60feb9a
ToppCell	tumor_Lymph_Node_/_Brain-Myeloid_cells-Activated_DCs\|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass	SIM2 BCOR NHSL1 COL14A1 DISP2	2.53e-04	180	139	5	aae85fb3c92a45614616a3ee3a1af5244cc299a7
ToppCell	droplet-Lung-immune-endo-depleted-3m-Mesenchymal-pericyte_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL7A1 UNC5B SLC6A9 PHLDB1 PDZD2	2.53e-04	180	139	5	0153667e44fdbc3c0d444dcb023069925a2b69a2
ToppCell	droplet-Lung-immune-endo-depleted-3m-Mesenchymal-Pericyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL7A1 UNC5B SLC6A9 PHLDB1 PDZD2	2.53e-04	180	139	5	40a28b410f46215d6d7cf8a02a18078eb046b5b0
ToppCell	10x3'2.3-week_17-19-Lymphocytic_NK-T_NK\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	SH2D2A SERPINA11 CD5 KIR2DL3 KIR3DL2	2.53e-04	180	139	5	0a98d21fec67a890e75ebf0e2d23adddd77da214
ToppCell	10x3'2.3-week_17-19-Lymphocytic_NK\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	SH2D2A SERPINA11 CD5 KIR2DL3 KIR3DL2	2.53e-04	180	139	5	1c8398342d3fa4d5ca9a8a63626cc497c5291446
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CACHD1 LLGL2 SHANK2 MICAL2 GAREM1	2.59e-04	181	139	5	576da14ab3107f89e1f44a4a439d1bef5bb42370
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Macula_Densa_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ERICH3 RGL3 SIM2 SLC45A4 LLGL2	2.59e-04	181	139	5	22363c5835dd6cef8f895ab9362e0837d92b15b1
ToppCell	droplet-Lung-LUNG-1m-Mesenchymal-pericyte_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAPK8IP1 COL7A1 SHD SLC6A9 PDZD2	2.66e-04	182	139	5	9edaccf1154cec92ca9a28e9b1f9075cfd422bfd
ToppCell	facs-Pancreas-Exocrine\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL7A1 SLC6A9 COL18A1 ADAMTS9 SPON1	2.66e-04	182	139	5	45faefd7cbeac84d2c58650530b902af6ce921f8
ToppCell	droplet-Heart-HEART-1m-Mesenchymal-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TROAP XRCC3 SHD SLC6A9 CEP72	2.66e-04	182	139	5	c84f44391932080df31c8765e363c3dff64b2bd1
ToppCell	droplet-Lung-LUNG-1m-Mesenchymal-Pericyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAPK8IP1 COL7A1 SHD SLC6A9 PDZD2	2.66e-04	182	139	5	aba4c06d5d7618ac21b2695bca8e7a1346a91090
ToppCell	Basal\|World / shred by cell class for mouse tongue	LARGE2 COL7A1 SIPA1L3 CACHD1 COL18A1	2.73e-04	183	139	5	c6729a207526ff4aa48176207b9353176f631fea
ToppCell	droplet-Lung-1m-Mesenchymal-myofibroblast-pericyte_cell-pericyte\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MAPK8IP1 COL7A1 SHD SLC6A9 PDZD2	2.80e-04	184	139	5	4cb5f299dd7413e0be1ad7af817ee614b23a18ae
ToppCell	droplet-Lung-1m-Mesenchymal-myofibroblast-pericyte_cell\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MAPK8IP1 COL7A1 SHD SLC6A9 PDZD2	2.80e-04	184	139	5	39bb0eb55bdc2cea46e41c7f21d8c5883f14e6bd
ToppCell	PCW_05-06-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^high_distal_(10)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	LARGE2 RGL3 RFX6 LLGL2 SHANK2	2.80e-04	184	139	5	fa4915b0498f3069fd5ef497286445528f75187e
ToppCell	droplet-Lung-nan-3m-Endothelial-endothelial_cell_of_lymphatic_vessel\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARHGAP32 UNC5B SYNPO COL18A1 CD5	2.87e-04	185	139	5	6a85399cfdb9b89683c874e7f046957f9a601dc2
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	PARP8 DGKA CACHD1 CD5 DCHS1	2.87e-04	185	139	5	847257d232b9993cad50c814fd4ffeef52385295
ToppCell	10x5'-lymph-node_spleen-Myeloid_Dendritic-Cycling_Dendritic\|lymph-node_spleen / Manually curated celltypes from each tissue	CENPE TROAP CNTLN GPR88 SEPTIN3	2.87e-04	185	139	5	912d8efdc37820dbb07736221a98af929e5a7c97
ToppCell	droplet-Lung-nan-3m-Endothelial-Lymphatic_endothelial_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARHGAP32 UNC5B SYNPO COL18A1 CD5	2.87e-04	185	139	5	64791056cdbb739136dbef08f4b16e2b5427faad
ToppCell	368C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	CDO1 SH2D2A PPP1R13L LLGL1 TTC31	2.87e-04	185	139	5	daea170d827226dda6750bf1838ffd82f070c4d4
ToppCell	COVID-19_Moderate-NK_activated\|World / disease group, cell group and cell class	ERICH3 SH2D2A LLGL2 KIR2DL3 KIR3DL2	2.94e-04	186	139	5	ff8f32f69516bf785224fa12f8139a95359b0279
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PDK4 RGL3 GRIN2C NHSL1 SPON1	3.01e-04	187	139	5	5d3d68519c8e19f10c29f9d81712125be78ca15a
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro-Astrocyte\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PDK4 RGL3 GRIN2C NHSL1 SPON1	3.01e-04	187	139	5	5c73010fe4c85fb5cc1273f5504821229ca0cc4b
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	KCNH7 RGL3 SIM2 COL14A1 GAREM1	3.01e-04	187	139	5	77886f99c229610abd28c4c370d2c7d1536c9782
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1-6_FGFR3_ETNPPL\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PDK4 RGL3 GRIN2C NHSL1 SPON1	3.01e-04	187	139	5	93c78fc7f126132eb84feb47be2c4e8c568b9e91
Drug	tetraethyltin	ETV6 DBH GAA	7.82e-06	7	140	3	CID000011704
Drug	17-DMAG; Down 200; 0.1uM; PC3; HT_HG-U133A	ATN1 SH2D2A SIM2 XRCC3 ARHGEF40 ALMS1 MICAL2 NFKBIB	2.46e-05	191	140	8	4437_DN
Drug	Zidovudine, AZT [30516-87-1]; Down 200; 15uM; PC3; HT_HG-U133A	COL7A1 TROAP XRCC3 PRR7 PHLDB1 PIK3R2 NFKBIB POLL	2.65e-05	193	140	8	6733_DN
Drug	prazosin hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA	TEAD3 PHC3 PHLDB1 SHANK2 ALMS1 PIK3R2 POLL HCFC1	2.75e-05	194	140	8	942_UP
Drug	W-13, hydrochloride; Up 200; 10uM; MCF7; HG-U133A	COL7A1 RHBDF2 ATG13 PRR7 LLGL2 LLGL1 FAM13A PIK3R2	2.75e-05	194	140	8	440_UP
Drug	Mifepristone [84371-65-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A	RNF31 RHBDF2 XRCC3 PPP1R13L PHC3 ALMS1 NFKBIB PRRC2B	2.96e-05	196	140	8	7183_DN
Drug	Diloxanide furoate [3736-81-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A	MIER2 MAP1A UNC5B ZC3H13 IL17RC PHC3 MICAL2 EPS8L3	3.07e-05	197	140	8	3399_UP
Drug	Sulfameter [651-06-9]; Up 200; 14.2uM; HL60; HT_HG-U133A	CDO1 ATN1 SIPA1L3 SIM2 SHANK2 ARSD COL14A1 SAMD14	3.07e-05	197	140	8	2712_UP
Drug	Flunixin meglumine [42461-84-7]; Down 200; 8.2uM; MCF7; HT_HG-U133A	DET1 INPP5K PPP1R13L ALMS1 PIK3R2 ZBTB3 HCFC1 PRRC2B	3.07e-05	197	140	8	3411_DN
Drug	Butirosin disulfate salt [51022-98-1]; Down 200; 5.4uM; HL60; HT_HG-U133A	ARHGAP32 SIPA1L3 MGAT3 NFKBIB CCDC106 REEP4 PRKAG2 GAA	3.07e-05	197	140	8	2518_DN
Drug	Nitrarine dihydrochloride [20069-05-0]; Up 200; 10.6uM; HL60; HT_HG-U133A	COL7A1 RHBDF2 ZC3H13 SIPA1L3 IL17RC PPFIA3 CD5 FAM13A	3.07e-05	197	140	8	2188_UP
Drug	Glafenine hydrochloride [65513-72-6]; Up 200; 9.8uM; MCF7; HT_HG-U133A	COL7A1 ATG13 IL17RC PHLDB1 CEP72 BRD4 PRKAG2 PRRC2B	3.18e-05	198	140	8	7018_UP
Drug	Amrinone [60719-84-8]; Down 200; 21.4uM; HL60; HT_HG-U133A	ARHGAP32 RHBDF2 PDK4 INPP5K BAHD1 PRR7 CCDC106 USP6NL	3.18e-05	198	140	8	2724_DN
Drug	Alfuzosin hydrochloride [81403-68-1]; Down 200; 9.4uM; MCF7; HT_HG-U133A	EPM2A ATN1 RNF31 ETV6 PPFIA3 ABLIM3 COL18A1 PHLDB1	3.18e-05	198	140	8	5242_DN
Drug	Riluzole hydrochloride; Down 200; 14.8uM; PC3; HT_HG-U133A	COL7A1 ARHGAP32 NRG2 SYNPO BAHD1 LUZP1 COL18A1 CCDC106	3.30e-05	199	140	8	7365_DN
Drug	Iobenguane sulfate; Down 200; 10.8uM; MCF7; HT_HG-U133A	TBC1D19 SIPA1L3 DGKA ETV6 PPFIA3 SIM2 ABLIM3 NFKBIB	3.30e-05	199	140	8	2878_DN
Drug	D-raffinose	CYC1 CDO1 PRR7 COL18A1 KIR3DL2 GAA	6.47e-05	111	140	6	CID000010542
Drug	D-Au	KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.13e-04	77	140	5	CID000277822
Drug	Rapamycin; Up 200; 0.1uM; PC3; HT_HG-U133A	CDO1 ATN1 PDK4 HBP1 ARHGEF40 ZBTB3 HCFC1	1.51e-04	185	140	7	4445_UP
Drug	Aa1	KIR2DL2 KIR2DL3 KIR2DS1 KIR2DS5 KIR3DL2	1.62e-04	83	140	5	CID009549188
Drug	C768-0445; Up 200; 10uM; MCF7; HT_HG-U133A_EA	UNC5B INPP5K HBP1 PPFIA3 PHC3 ALMS1 ATXN1	1.72e-04	189	140	7	973_UP
Drug	Hexetidine [141-94-6]; Up 200; 11.8uM; PC3; HT_HG-U133A	COL7A1 INPP5K SIPA1L3 LLGL1 ATXN1 MICAL2 HCFC1	1.84e-04	191	140	7	6319_UP
Drug	LY 294002; Up 200; 10uM; PC3; HT_HG-U133A	PDK4 HBP1 CT62 ARSD ALMS1 ATXN1 EPS8L3	1.84e-04	191	140	7	4451_UP
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA	INPP5K HBP1 TEAD3 PPP1R13L ABLIM3 LUZP1 POLL	1.84e-04	191	140	7	1080_UP
Drug	Galanthamine hydrobromide [1953-04-4]; Down 200; 10.8uM; PC3; HT_HG-U133A	ATN1 PDK4 IL17RC TEAD3 XRCC3 HCFC1 PRRC2B	1.96e-04	193	140	7	4186_DN
Drug	Oxyphenbutazone [129-20-4]; Up 200; 12.4uM; PC3; HT_HG-U133A	COL7A1 EPM2A ETV6 HBP1 ARSD SPON1 NFKBIB	2.02e-04	194	140	7	4506_UP
Drug	0173570-0000 [211245-44-2]; Down 200; 1uM; MCF7; HT_HG-U133A	COL7A1 TEAD3 BCOR CEP350 BRD4 NFKBIB HCFC1	2.02e-04	194	140	7	4715_DN
Drug	Moxalactam disodium salt [64953-12-4]; Up 200; 7uM; MCF7; HT_HG-U133A	ATN1 MAP1A SYNPO IL17RC ARHGEF40 LLGL1 POLL	2.02e-04	194	140	7	5609_UP
Drug	Pronethalol hydrochloride [51-02-5]; Down 200; 15uM; MCF7; HT_HG-U133A	INPP5K SIPA1L3 SIM2 LUZP1 PHC3 BRD4 GAREM1	2.02e-04	194	140	7	7322_DN
Drug	Indoprofen [31842-01-0]; Down 200; 14.2uM; PC3; HT_HG-U133A	ATN1 NRG2 SH2D2A PRR7 COL18A1 POLL HCFC1	2.02e-04	194	140	7	4249_DN
Drug	S(+)-Terguride [37686-84-3]; Up 200; 11.8uM; PC3; HT_HG-U133A	COL7A1 SIPA1L3 CNTLN PPFIA3 PHLDB1 EPS8L3 REEP4	2.09e-04	195	140	7	6299_UP
Drug	Bumetanide [28395-03-1]; Down 200; 11uM; PC3; HT_HG-U133A	ARHGAP32 MAP1A ATG13 BAHD1 ASH2L COL18A1 POLL	2.09e-04	195	140	7	5117_DN
Drug	Acacetin [480-44-4]; Up 200; 14uM; MCF7; HT_HG-U133A	MIER2 COL7A1 MGAT3 SHANK2 ADAMTS9 COL14A1 POLL	2.09e-04	195	140	7	3942_UP
Drug	5255229; Up 200; 13uM; MCF7; HT_HG-U133A_EA	RNF31 MAP1A SIM2 PHLDB1 PIK3R2 HCFC1 GAREM1	2.15e-04	196	140	7	833_UP
Drug	nordihydroguaiaretic acid; Down 200; 1uM; MCF7; HG-U133A	SYNPO TEAD3 ABLIM3 LUZP1 PHLDB1 CD5 NFKBIB	2.15e-04	196	140	7	203_DN
Drug	Nefopam hydrochloride [23327-57-3]; Up 200; 13.8uM; MCF7; HT_HG-U133A	ATN1 SIPA1L3 SYNPO SIM2 PHLDB1 ARSD SPON1	2.15e-04	196	140	7	4752_UP
Drug	Racecadotril [81110-73-8]; Up 200; 10.4uM; MCF7; HT_HG-U133A	MIER2 EPM2A PPFIA3 PHLDB1 ARHGEF40 SPON1 NFKBIB	2.15e-04	196	140	7	2774_UP
Drug	ICI 182,780; Down 200; 1uM; HL60; HT_HG-U133A	RNF31 ATG13 BAHD1 ARHGEF40 ALMS1 NFKBIB REEP4	2.15e-04	196	140	7	1146_DN
Drug	Cefmetazole sodium salt [56796-39-5]; Down 200; 8.2uM; MCF7; HT_HG-U133A	EPM2A ATG13 INPP5K XRCC3 BAHD1 NFKBIB HCFC1	2.15e-04	196	140	7	7222_DN
Drug	Chlorzoxazone [95-25-0]; Up 200; 23.6uM; HL60; HG-U133A	ATN1 MAP1A IL17RC SH2D2A COL18A1 PHLDB1 SAMD14	2.15e-04	196	140	7	1416_UP
Drug	Pentetic acid [67-43-6]; Up 200; 10.2uM; MCF7; HT_HG-U133A	CDO1 COL7A1 ATN1 CNTLN LLGL1 MICAL2 POLL	2.15e-04	196	140	7	5629_UP
Drug	estradiol, USP; Up 200; 0.1uM; MCF7; HT_HG-U133A	MAP1A SIPA1L3 NRG2 PPFIA3 ARSD SPON1 COL14A1	2.15e-04	196	140	7	6928_UP
Drug	Meptazinol hydrochloride [59263-76-2]; Down 200; 14.8uM; MCF7; HT_HG-U133A	ARHGAP32 INPP5K WDR18 IL17RC PPFIA3 ABLIM3 SHANK2	2.22e-04	197	140	7	4774_DN
Drug	Sulfamethizole [144-82-1]; Up 200; 14.8uM; MCF7; HT_HG-U133A	TBC1D19 ATN1 CNTLN PHLDB1 ARHGEF40 LLGL1 SHANK2	2.22e-04	197	140	7	6099_UP
Drug	2-propylpentanoic acid; Down 200; 50uM; MCF7; HT_HG-U133A	FRYL PPFIA3 ALMS1 CEP72 PIK3R2 REEP4 HCFC1	2.22e-04	197	140	7	6941_DN
Drug	Lisinopril [83915-83-7]; Up 200; 9uM; HL60; HT_HG-U133A	SH2D2A CNTLN TEAD3 CD5 BRD4 DCHS1 EPS8L3	2.22e-04	197	140	7	2371_UP
Drug	Flutamide [13311-84-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A	COL7A1 ATN1 IL17RC PPFIA3 SIM2 ALMS1 NFKBIB	2.22e-04	197	140	7	3885_DN
Drug	0393-0188; Up 200; 10uM; PC3; HT_HG-U133A	SIPA1L3 TEAD3 MICAL2 NFKBIB ZBTB3 HCFC1 PRRC2B	2.22e-04	197	140	7	7510_UP
Drug	Rapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A	INPP5K SIPA1L3 LLGL1 BRD4 NFKBIB HCFC1 GAREM1	2.22e-04	197	140	7	2702_DN
Drug	Meglumine [6284-40-8]; Up 200; 20.4uM; MCF7; HT_HG-U133A	TEAD3 ABLIM3 CEP72 POLL ZBTB3 HCFC1 GAREM1	2.22e-04	197	140	7	5285_UP
Drug	Indoprofen [31842-01-0]; Down 200; 14.2uM; HL60; HT_HG-U133A	SIPA1L3 NRG2 MGAT3 FAM13A BRD4 NFKBIB COL14A1	2.22e-04	197	140	7	3007_DN
Drug	Pirenzepine dihydrochloride [29868-97-1]; Up 200; 9.4uM; HL60; HG-U133A	ARHGAP32 ATN1 ATG13 HBP1 PPFIA3 LLGL1 CEP72	2.22e-04	197	140	7	1388_UP
Drug	Glimepiride [93479-97-1]; Up 200; 8.2uM; MCF7; HT_HG-U133A	ARHGEF40 FCGRT SPON1 NFKBIB COL14A1 HCFC1 PDZD2	2.22e-04	197	140	7	2809_UP
Drug	Epitiostanol [2363-58-8]; Down 200; 13uM; MCF7; HT_HG-U133A	RNF31 SIPA1L3 PPFIA3 SIM2 PHC3 PIK3R2 HCFC1	2.22e-04	197	140	7	7342_DN
Drug	Carbarsone [121-59-5]; Down 200; 15.4uM; MCF7; HT_HG-U133A	RNF31 SIPA1L3 DGKA PPP1R13L ALMS1 NFKBIB PRRC2B	2.22e-04	197	140	7	3250_DN
Drug	Azathymine, 6 [932-53-6]; Up 200; 31.4uM; HL60; HT_HG-U133A	CDO1 PDK4 NRG2 SH2D2A TEAD3 CD5 NFKBIB	2.22e-04	197	140	7	2466_UP
Drug	Morantel tartrate [26155-31-7]; Down 200; 10.8uM; MCF7; HT_HG-U133A	RHBDF2 INPP5K LUZP1 ALMS1 NFKBIB HCFC1 GAREM1	2.29e-04	198	140	7	7010_DN
Drug	Levamisole hydrochloride [16595-80-5]; Up 200; 16.6uM; PC3; HT_HG-U133A	PDK4 CNTLN PHLDB1 SHANK2 SPON1 EPS8L3 HCFC1	2.29e-04	198	140	7	2094_UP
Drug	rotenone; Down 200; 1uM; MCF7; HT_HG-U133A	ATN1 MAP1A INPP5K PPFIA3 PHLDB1 NFKBIB ZBTB3	2.29e-04	198	140	7	5943_DN
Drug	Cisapride [81098-60-4]; Down 200; 8.6uM; MCF7; HT_HG-U133A	TBC1D19 COL7A1 EPM2A UNC5B ABLIM3 ALMS1 PRRC2B	2.29e-04	198	140	7	3305_DN
Drug	Finasteride [98319-26-7]; Up 200; 10.8uM; HL60; HT_HG-U133A	TBC1D19 PDK4 DBH PHLDB1 LLGL1 SHANK2 POLL	2.29e-04	198	140	7	2206_UP
Drug	Gramine [87-52-5]; Down 200; 23uM; MCF7; HT_HG-U133A	EPM2A PPFIA3 BCOR ALMS1 MICAL2 NFKBIB ZBTB3	2.29e-04	198	140	7	2799_DN
Drug	Butirosin disulfate salt [51022-98-1]; Up 200; 5.4uM; HL60; HT_HG-U133A	COL7A1 ATN1 DGKA LLGL1 MICAL2 USP6NL PDZD2	2.29e-04	198	140	7	2518_UP
Drug	Metampicillin sodium salt [6489-61-8]; Down 200; 10.4uM; PC3; HT_HG-U133A	TBC1D19 IL17RC BAHD1 PRR7 PHC3 ALMS1 PRRC2B	2.29e-04	198	140	7	2123_DN
Drug	Apramycin [37321-09-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A	RNF31 INPP5K PPFIA3 XRCC3 LUZP1 HCFC1 PRRC2B	2.29e-04	198	140	7	7334_DN
Drug	Orphenadrine hydrochloride [341-69-5]; Up 200; 13uM; MCF7; HT_HG-U133A	CDO1 SLC6A9 LLGL1 ARSD SPON1 COL14A1 POLL	2.29e-04	198	140	7	3883_UP
Drug	nordihydroguaiaretic acid; Down 200; 1uM; MCF7; HT_HG-U133A	EPM2A IL17RC ABLIM3 LUZP1 MICAL2 SPEN HCFC1	2.29e-04	198	140	7	6983_DN
Drug	Gliquidone [33342-05-1]; Down 200; 7.6uM; MCF7; HT_HG-U133A	INPP5K PPFIA3 SIM2 ABLIM3 MICAL2 NFKBIB PRKAG2	2.29e-04	198	140	7	6505_DN
Drug	Furaltadone hydrochloride [3759-92-0]; Down 200; 11uM; PC3; HT_HG-U133A	ATN1 DGKA PHC3 NFKBIB POLL HCFC1 PRRC2B	2.29e-04	198	140	7	3756_DN
Drug	Dipyridamole [58-32-2]; Up 200; 8uM; MCF7; HT_HG-U133A	SH2D2A GRIN2C CNTLN PHLDB1 SPON1 POLL EPS8L3	2.29e-04	198	140	7	5617_UP
Drug	Methyldopate hydrochloride [2508-79-4]; Up 200; 14.6uM; PC3; HT_HG-U133A	DBH CEP350 PHLDB1 LLGL1 NFKBIB HCFC1 USP6NL	2.29e-04	198	140	7	6640_UP
Drug	Neostigmine bromide [114-80-7]; Down 200; 13.2uM; MCF7; HT_HG-U133A	ATG13 SIPA1L3 DGKA ABLIM3 BAHD1 CEP350 ALMS1	2.29e-04	198	140	7	5335_DN
Drug	rosiglitazone; Down 200; 10uM; HL60; HT_HG-U133A	ARHGAP32 RHBDF2 INPP5K DBH MGAT3 CCDC106 HCFC1	2.36e-04	199	140	7	2693_DN
Drug	CAY10397; Down 200; 10uM; PC3; HT_HG-U133A	RHBDF2 INPP5K ETV6 FRYL PPFIA3 PRR7 SHANK2	2.36e-04	199	140	7	7071_DN
Drug	Pentoxifylline [6493-05-6]; Down 200; 14.4uM; PC3; HT_HG-U133A	COL7A1 NRG2 WDR18 TEAD3 FAM13A CCDC106 PRRC2B	2.36e-04	199	140	7	2127_DN
Drug	Tubocurarine chloride pentahydrate (+) [6989-98-6]; Down 200; 5.2uM; PC3; HT_HG-U133A	RHBDF2 NRG2 COL18A1 ARHGEF40 SHANK2 TTC31 REEP4	2.36e-04	199	140	7	6351_DN
Drug	Cephalosporanic acid, 7-amino [957-68-6]; Up 200; 14.6uM; MCF7; HT_HG-U133A	MIER2 ZC3H13 NRG2 PHC3 MGAT3 ALMS1 PDZD2	2.36e-04	199	140	7	4826_UP
Drug	Vinpocetine [42971-09-5]; Down 200; 11.4uM; PC3; HT_HG-U133A	SIPA1L3 NRG2 IL17RC TEAD3 BAHD1 ALMS1 PRRC2B	2.36e-04	199	140	7	5859_DN
Drug	Metoclopramide monohydrochloride [7232-21-5]; Up 200; 11.8uM; MCF7; HT_HG-U133A	COL7A1 MAP1A NRG2 MGAT3 MICAL2 SPON1 PDZD2	2.36e-04	199	140	7	3625_UP
Drug	Esculetin [305-01-1]; Down 200; 22.4uM; MCF7; HT_HG-U133A	MAP1A PDK4 ATG13 XRCC3 ABLIM3 LUZP1 HCFC1	2.36e-04	199	140	7	6499_DN
Drug	Sulfameter [651-06-9]; Up 200; 14.2uM; MCF7; HT_HG-U133A	ATN1 SIPA1L3 DBH ABLIM3 CEP350 MGAT3 SPON1	2.36e-04	199	140	7	6212_UP
Drug	Dantrolene sodium salt [14663-23-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A	TBC1D19 MIER2 HBP1 PPFIA3 SIM2 NFKBIB POLL	2.36e-04	199	140	7	2329_UP
Drug	aspirin, USP; Up 200; 100uM; HL60; HT_HG-U133A	ZC3H13 SH2D2A PRR7 SHANK2 FAM13A SPON1 PDZD2	2.36e-04	199	140	7	6164_UP
Drug	Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride; Up 200; 16.4uM; MCF7; HT_HG-U133A	ATN1 PDK4 ZC3H13 PARP8 NRG2 GRIN2C COL14A1	2.36e-04	199	140	7	4810_UP
Drug	Tetrahydrozoline hydrochloride [522-48-5]; Up 200; 16.8uM; MCF7; HT_HG-U133A	MAP1A KIAA0319 PHC3 PHLDB1 ARHGEF40 MGAT3 ADAMTS9	2.36e-04	199	140	7	6069_UP
Drug	Carbenoxolone disodium salt [7421-40-1]; Up 200; 6.6uM; MCF7; HT_HG-U133A	ATN1 INPP5K ZC3H13 IL17RC SH2D2A SPON1 NFKBIB	2.36e-04	199	140	7	3353_UP
Drug	Molsidomine [25717-80-0]; Up 200; 16.6uM; MCF7; HT_HG-U133A	ATN1 PDK4 ETV6 IL17RC COL18A1 MGAT3 POLL	2.36e-04	199	140	7	5426_UP
Drug	Methiothepin maleate [19728-88-2]; Down 200; 8.4uM; PC3; HT_HG-U133A	DET1 RNF31 MAP1A INPP5K SH2D2A PIK3R2 HCFC1	2.36e-04	199	140	7	6312_DN
Drug	Tubocurarine chloride pentahydrate (+) [6989-98-6]; Up 200; 5.2uM; MCF7; HT_HG-U133A	ATN1 IL17RC ARHGEF40 LLGL1 FAM13A SPON1 COL14A1	2.36e-04	199	140	7	5449_UP
Drug	S(+)-Terguride [37686-84-3]; Up 200; 11.8uM; MCF7; HT_HG-U133A	TBC1D19 MAP1A INPP5K PPFIA3 NFKBIB COL14A1 PDZD2	2.36e-04	199	140	7	6459_UP
Drug	Pantothenic acid calcium salt monohydrate [63409-48-3]; Up 200; 8uM; MCF7; HT_HG-U133A	MIER2 SIPA1L3 SYNPO BAHD1 CD5 ADAMTS9 BRD4	2.36e-04	199	140	7	4775_UP
Drug	Ab-9	KIR2DL2 KIR2DL3 KIR3DL2	2.79e-04	21	140	3	CID006540280
Disease	kidney cancer (implicated_via_orthology)	LLGL2 LLGL1 SCRIB	1.41e-05	11	132	3	DOID:263 (implicated_via_orthology)
Disease	neuroblastoma (implicated_via_orthology)	LLGL2 LLGL1	1.97e-04	5	132	2	DOID:769 (implicated_via_orthology)
Disease	X-13553 measurement	DBH ARSD	2.94e-04	6	132	2	EFO_0021355
Disease	interleukin 7 measurement	PARP8 DCHS1 PDZD2	1.08e-03	45	132	3	EFO_0008189
Disease	Abruptio Placentae	GALNT15 INSYN2B	1.27e-03	12	132	2	EFO_1001754
Disease	mean corpuscular hemoglobin concentration	CYC1 MAPK8IP1 ATN1 SERTAD2 ZDHHC5 FBRSL1 ETV6 MIDEAS SLC6A9 ATXN1 BRD4 PRKAG2 GAA	1.40e-03	1105	132	13	EFO_0004528
Disease	Vitiligo, response to rhododendrol	PPFIA3 MICAL2	1.50e-03	13	132	2	EFO_0004208, EFO_0010824
Disease	uric acid measurement	SIPA1L3 ZDHHC5 FBRSL1 HBP1 CNTROB KIAA0319 PRKAG2 PRRC2B GAREM1	1.74e-03	610	132	9	EFO_0004761
Disease	trait in response to apixaban	MIER2 ABLIM3 CNTROB SPON1	1.80e-03	115	132	4	OBA_2050328
Disease	N-acetylmethionine measurement	ALMS1 MICAL2	2.01e-03	15	132	2	EFO_0021427
Disease	Familial Progressive Myoclonic Epilepsy	EPM2A ATN1	2.58e-03	17	132	2	C0751777
Disease	Atypical Inclusion-Body Disease	EPM2A ATN1	2.58e-03	17	132	2	C0751776
Disease	Myoclonic Epilepsies, Progressive	EPM2A ATN1	2.58e-03	17	132	2	C0751778
Disease	Biotin-Responsive Encephalopathy	EPM2A ATN1	2.58e-03	17	132	2	C0751780
Disease	May-White Syndrome	EPM2A ATN1	2.58e-03	17	132	2	C0751782
Disease	Dentatorubral-Pallidoluysian Atrophy	EPM2A ATN1	2.58e-03	17	132	2	C0751781
Disease	Action Myoclonus-Renal Failure Syndrome	EPM2A ATN1	2.90e-03	18	132	2	C0751779
Disease	carcinoma (implicated_via_orthology)	LLGL2 LLGL1 SCRIB	2.99e-03	64	132	3	DOID:305 (implicated_via_orthology)
Disease	apolipoprotein B measurement	RBM4 SERTAD2 PPP1R13L PKD1L3 MIDEAS LLGL1 UBXN2B FCGRT EPS8L3	3.04e-03	663	132	9	EFO_0004615
Disease	cerebellar cortex volume measurement	SIM2 VSIG10L2	3.94e-03	21	132	2	EFO_0010291
Disease	cortical thickness	ESPNL LUZP1 SLC45A4 NHSL1 COL18A1 PHLDB1 ARHGEF40 ADAMTS9 CBY2 PRKAG2 WNK2 PDZD2	4.31e-03	1113	132	12	EFO_0004840

Protein segments in the cluster

Peptide	Gene	Start	Entry
GHSSPLALTAPRPYT	ERICH3	141	Q5RHP9
DPYSAPGRLPAHSVA	EPM2A	226	B3EWF7
LSAESFLPTASPAPH	FBRSL1	256	Q9HCM7
HYPQDLARPLFPSTG	FBRSL1	641	Q9HCM7
GSPRSHYLADSDPLI	ABLIM3	566	O94929
PLASPTHYAPSKAAA	PRKAG2	216	Q9UGJ0
PRDVYSNLSHLPGAP	B4GALT3	51	O60512
ARPLTPDSEPLYHAV	ARSD	526	P51689
IIDHFVDRPYPSSSP	ATG13	211	O75143
PPPSRDTLNTTLHYL	ARHGEF40	561	Q8TER5
DPDYSAQVPHRPSLS	CNTLN	441	Q9NXG0
SDPYSTGHLREAPSP	BRD4	1051	O60885
DPLASGSHLTRIPYP	ATN1	1081	P54259
PSAPSSFYSHREKPI	ALMS1	901	Q8TCU4
PSVLYPQVLSDSHLP	ALMS1	1056	Q8TCU4
DVLARTYPHPRSSPA	AJM1	386	C9J069
PPRNSHLSAYPALEG	CD5	456	P06127
SLTRPYLLSEPPLHT	CACHD1	521	Q5VU97
EASRAPRPHTYFTPH	CEP72	286	Q9P209
AVSASDLELHPPSYP	CYC1	81	P08574
VVVHPSPSDYSSRDP	ATXN1	361	P54253
TPNPRSPLEDYSLHI	DET1	181	Q7L5Y6
PRVHLPTQPAADTYS	BCOR	341	Q6W2J9
SPLAPAHFTYPRALQ	DISP2	86	A7MBM2
HSYPRSPPADVSTLP	CCER1	156	Q8TC90
SDPLFSAQRLPPHGY	ASH2L	316	Q9UBL3
SIFIPSRYLDHPQPS	POLL	131	Q9UGP5
PYDRHLLPTSGAAAT	RBM4	271	Q9BWF3
TSPSVIYRPHPSALS	RAB3IP	51	Q96QF0
SSIRSLPPYSDIHDP	RFX6	826	Q8HWS3
PHAPSLDISRFRSSP	LARGE2	666	Q8N3Y3
HSPYQLSAPSDPLDI	KIR2DS2	106	P43631
HSPYQLSAPSDPLDI	KIR3DL2	201	P43630
AVPAPYLAPLHSSAI	LLGL1	381	Q15334
PREVEHFSRYSPSPL	PDK4	21	Q16654
SYASSTPLHVPVPRA	ETV6	26	P41212
ITYGVLPPPRESHTA	HCFC1	191	P51610
ARAIFPPASHRSPIS	DCHS1	3226	Q96JQ0
PHVDGAPVPYSSLSL	ESPNL	841	Q6ZVH7
HLFSTLRRSPSYPPP	PARP8	281	Q8N3A8
HSPYQLSAPSDPLDI	KIR2DL2	106	P43627
APPRVHYPALLAAAA	GPR88	186	Q9GZN0
ERPAPPRFHTSTYDL	MAP1A	761	P78559
FPHQPSALGYSPSLR	LLGL2	31	Q6P1M3
GPDLLRTPLYSHSPL	MGAT3	66	Q09327
HSPYQLSAPSDPLDI	KIR2DL3	106	P43628
AAYPSTAGRPHPSIS	MAPK8IP1	316	Q9UQF2
TYVHPIRHPSLPDSS	KCNH7	1161	Q9NS40
YPSKADLATAPPHVT	LRRC47	566	Q8N1G4
APTLPSGAHLDPYVA	PPFIA3	521	O75145
GHLLTTIPSPYPASE	DCAF4L2	346	Q8NA75
LYGAPSQAPLPHSRS	CCDC120	601	Q96HB5
LYPSEPRPSFSGKLH	GALNT15	496	Q8N3T1
LDSPASPIRYSILPH	CDH24	401	Q86UP0
SPIRYSILPHSDPER	CDH24	406	Q86UP0
PDRTPDTNHTPVALY	NFKBIB	166	Q15653
HRAFSRSDVPYPLLS	IBA57-DT	6	B1ANH7
RASPLKPHLATPGYS	NHSL1	566	Q5SYE7
LYHLTAVSSPAPGTP	FCGRT	31	P55899
PSGEDHLYFTPRPAT	PDZD2	2206	O15018
SSYVHLRPARPTSPP	COL18A1	1556	P39060
RHTSAREPSAFTLPP	EPS8L3	211	Q8TE67
YPFSSPLHLQLAPRS	GAREM1	781	Q9H706
DYVPETSSPGLPLHR	FRYL	1581	O94915
AHAVSLPPAAPISYR	NRG2	626	O14511
RVPVLYHESPPAAAA	HMX1	281	Q9NP08
DHILPPSSIYPSVLA	DGKA	326	P23743
TLPVRPSASYHSPEL	LMLN2	761	A0A1B0GTW7
FAPPAAAAEPHSLRY	MICB	16	Q29980
PAVGSYLPPTARAHS	PARP4	1321	Q9UKK3
YLPPTARAHSPASLS	PARP4	1326	Q9UKK3
PGFPHPQSRTYATAL	ARHGAP32	2051	A7KAX9
SYTLSPHPPILAALH	RGL3	471	Q3MIN7
ERPLSPFYLSAHVPQ	FAM13A	341	O94988
LIAPASYSPIQPHSL	PHC3	291	Q8NDX5
HSPYQLSAPSDPLDI	KIR2DS5	106	Q14953
LDRGYTSALHLPSAP	PRR7	206	Q8TB68
DSESHYRPELPAPRT	PIK3R2	141	O00459
AEPFPRLHNLYSTPR	CBY2	56	Q8NA61
HPPPAAPETRRSTYS	ADAMTS9	1166	Q9P2N4
APHLDPQIFYSLSPS	CCDC106	26	Q9BWC9
TLGSATIPYELPPHS	FBXO15	326	Q8NCQ5
SHTEPAVSLHLYSPP	CDO1	146	Q16878
SQPTRYLHPEGLPSD	COL14A1	1271	Q05707
GDRASLTSDVYPHPP	FRMPD3	1436	Q5JV73
PIPPASHFSLSLRGY	INPP5K	286	Q9BT40
ALQGSAPRESPLPYH	DBH	36	P09172
PVPLYSHLNSESSIP	CEP350	1931	Q5VT06
ALVPPSADYSTPPHR	BAHD1	736	Q8TBE0
SADYSTPPHRTVPED	BAHD1	741	Q8TBE0
ETPHVHSRAPSPLYS	GAA	196	P10253
PSVLSRYPPAAQEHS	LUZP1	471	Q86V48
HPALAYSLPQSPIVR	GLMP	306	Q8WWB7
ADHPSERSFELPPYT	MIDEAS	641	Q6PJG2
ATSKSLHSYARPPPV	HBP1	141	O60381
LHSYARPPPVSSSSK	HBP1	146	O60381
LSYSHRPSPLFPLNG	COL7A1	1096	Q02388
SYRRLSPPHLTDQPS	CT62	6	P0C5K7
PFGRSESAPTLHPYS	PPP1R13L	96	Q8WUF5
DSRSKSLPSPHPVRY	CENPE	2646	Q02224
TARAQLYLPSTSPPH	CNTROB	51	Q8N137
SRALQPALDSYFHPP	IL17RC	756	Q8NAC3
LSSNPYLLTHPSDPL	LILRA3	401	Q8N6C8
SAFSPPDPALRTHSL	MICAL2	1596	O94851
PLSHRPPALADPASY	MIER2	441	Q8N344
LRSISDAPAPAYHDP	REEP4	156	Q9H6H4
HSPYQLSAPSDPLDI	KIR2DS1	106	Q14954
IRPLTSLDHPQSPFY	SPON1	376	Q9HCB6
FPSVPELVLHYSSRP	SHD	306	Q96IW2
TAHPLSPYGETLTEP	SH2D2A	171	Q9NP31
ASRSPARTPPASLYH	SYNPO	776	Q8N3V7
PLDHRGYQSLSDSPP	SEMA4B	781	Q9NPR2
PLSSYTLGHPAPVRL	PKD1L3	431	Q7Z443
PPANTARHSLVPSYE	SIM2	511	Q14190
PERYTAAPHPLLSLD	SIPA1L3	1176	O60292
PSPLTRYRPLHNAAS	SAMD14	116	Q8IZD0
LSSDFRPSLPLPHFN	WDR18	326	Q9BV38
LLPHSEYSRPNRVPF	WDR20	26	Q8TBZ3
YRAFAAVPTSHPPED	SCRIB	1321	Q14160
YVHPLTGRLLDPSSP	SHANK2	1201	Q9UPX8
SSPIPAQHAPRPYAS	RNF31	436	Q96EP0
EPSIFHDASYPATPR	SLC45A4	331	Q5BKX6
LYPPSPRKHAEPSSS	USP6NL	581	Q92738
SPRTPPQRFYSSEHE	UBXN2B	56	Q14CS0
PSITYSIRPEALHSP	SPEN	3106	Q96T58
TPSLAAYRHPDFPLL	ERVFRD-1	11	P60508
SEPAPAYHRITPTIT	SERPINA11	41	Q86U17
PSDSYREAPPAFSHL	SERTAD2	96	Q14140
YFISPTGHSLRPLDL	SEPTIN3	176	Q9UH03
LSSYEPLAPLPSAAA	TEAD3	196	Q99594
AYLAPRTPTHRLDPA	TROAP	171	Q12815
TPTRTPVDFYPSALH	PRRC2B	686	Q5JSZ5
HRTGRYAPTIAPSPE	SLC6A9	661	P48067
VPPLVPARSSSYHLA	PHLDB1	281	Q86UU1
PARSSSYHLALQPPQ	PHLDB1	286	Q86UU1
LPPGTYPSDFARDTH	UNC5B	506	Q8IZJ1
SRHPSYRSEPSLEPE	ZDHHC5	391	Q9C0B5
LPRTDGPPDLDSHSY	ZGRF1	1071	Q86YA3
LASPHSLRYSAPPDV	WNK2	1796	Q9Y3S1
YAARHPETFPRLETP	VSIG10L2	726	P0DP72
YFRGIPHSASPVSPD	RHBDF2	316	Q6PJF5
AVYSELSVFPLPSHP	TBC1D19	66	Q8N5T2
RVLSAPHLPPSSCSY	XRCC3	316	O43542
PLRRSASPYPSHSLS	ZC3H13	366	Q5T200
ALRSPGLSPLLHYPS	TTC31	461	Q49AM3
LPAPASLHEPLYLSS	ZBTB3	441	Q9H5J0
TRHHLPPTYSLSFPR	INSYN2B	71	A6NMK8
DHQFLLYSGRSPPTP	KIAA2013	241	Q8IYS2
HYLNESASTPAPKLP	KIAA0319	216	Q5VV43
PLSPARCHYSSFPRA	GRIN2C	1021	Q14957